“We look forward to presenting updated data from our ongoing Phase 2 clinical study of palazestrant in combination with ribociclib in frontline metastatic breast cancer patients at SABCS in December.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback